| Dr Sameer Bellapravalu, MD | |
|
1 Hospital Drive Room 313, Psychiatry Dept Dc067.00, Columbia, MO 65212-0001 | |
| (573) 884-6136 | |
| (573) 884-1070 |
| Full Name | Dr Sameer Bellapravalu |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 22 Years |
| Location | 1 Hospital Drive Room 313, Columbia, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013030022 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 2010006687 (Missouri) | Secondary |
| 2084P0015X | Psychiatry & Neurology - Psychosomatic Medicine | 2010006687 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Banner Desert Medical Center | Mesa, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Apollo Hospitalists Pllc | 7618070640 | 17 |
| Banner Hospital Based Physicians Arizona Llc | 3274782487 | 398 |
News Archive
"The Global Fund to Fight AIDS, Tuberculosis and Malaria signed a grant agreement worth $102 million with the Churches Health Association of Zambia [CHAZ] Wednesday," Devex's "Development Newswire" reports.
Tolerx, Inc., today announced the publication in Diabetologia, the journal of the European Association for the Study of Diabetes, of the four-year follow-up clinical data from new onset type 1 diabetes (T1DM) patients (age 12-39) who received a single short course of therapy with otelixizumab (ChAglyCD3).
Adam Rose, MD, MSc, an assistant professor of medicine at Boston University School of Medicine, has accepted the Society of General Internal Medicine's New England Region 2011 Clinician Investigator Award for his contributions to quality of care research.
On March 28, the U.S. Food and Drug Administration approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS).
› Verified 2 days ago
| Entity Name | Apollo Hospitalists Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720120678 PECOS PAC ID: 7618070640 Enrollment ID: O20070313000384 |
News Archive
"The Global Fund to Fight AIDS, Tuberculosis and Malaria signed a grant agreement worth $102 million with the Churches Health Association of Zambia [CHAZ] Wednesday," Devex's "Development Newswire" reports.
Tolerx, Inc., today announced the publication in Diabetologia, the journal of the European Association for the Study of Diabetes, of the four-year follow-up clinical data from new onset type 1 diabetes (T1DM) patients (age 12-39) who received a single short course of therapy with otelixizumab (ChAglyCD3).
Adam Rose, MD, MSc, an assistant professor of medicine at Boston University School of Medicine, has accepted the Society of General Internal Medicine's New England Region 2011 Clinician Investigator Award for his contributions to quality of care research.
On March 28, the U.S. Food and Drug Administration approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS).
› Verified 2 days ago
| Entity Name | Banner Cancer Center Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518253152 PECOS PAC ID: 6103097779 Enrollment ID: O20110913000224 |
News Archive
"The Global Fund to Fight AIDS, Tuberculosis and Malaria signed a grant agreement worth $102 million with the Churches Health Association of Zambia [CHAZ] Wednesday," Devex's "Development Newswire" reports.
Tolerx, Inc., today announced the publication in Diabetologia, the journal of the European Association for the Study of Diabetes, of the four-year follow-up clinical data from new onset type 1 diabetes (T1DM) patients (age 12-39) who received a single short course of therapy with otelixizumab (ChAglyCD3).
Adam Rose, MD, MSc, an assistant professor of medicine at Boston University School of Medicine, has accepted the Society of General Internal Medicine's New England Region 2011 Clinician Investigator Award for his contributions to quality of care research.
On March 28, the U.S. Food and Drug Administration approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS).
› Verified 2 days ago
| Entity Name | Banner Hospital Based Physicians Arizona Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275889891 PECOS PAC ID: 3274782487 Enrollment ID: O20121003000752 |
News Archive
"The Global Fund to Fight AIDS, Tuberculosis and Malaria signed a grant agreement worth $102 million with the Churches Health Association of Zambia [CHAZ] Wednesday," Devex's "Development Newswire" reports.
Tolerx, Inc., today announced the publication in Diabetologia, the journal of the European Association for the Study of Diabetes, of the four-year follow-up clinical data from new onset type 1 diabetes (T1DM) patients (age 12-39) who received a single short course of therapy with otelixizumab (ChAglyCD3).
Adam Rose, MD, MSc, an assistant professor of medicine at Boston University School of Medicine, has accepted the Society of General Internal Medicine's New England Region 2011 Clinician Investigator Award for his contributions to quality of care research.
On March 28, the U.S. Food and Drug Administration approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS).
› Verified 2 days ago
| Entity Name | Banner - University Hospital Based Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750751566 PECOS PAC ID: 1052614294 Enrollment ID: O20160122000508 |
News Archive
"The Global Fund to Fight AIDS, Tuberculosis and Malaria signed a grant agreement worth $102 million with the Churches Health Association of Zambia [CHAZ] Wednesday," Devex's "Development Newswire" reports.
Tolerx, Inc., today announced the publication in Diabetologia, the journal of the European Association for the Study of Diabetes, of the four-year follow-up clinical data from new onset type 1 diabetes (T1DM) patients (age 12-39) who received a single short course of therapy with otelixizumab (ChAglyCD3).
Adam Rose, MD, MSc, an assistant professor of medicine at Boston University School of Medicine, has accepted the Society of General Internal Medicine's New England Region 2011 Clinician Investigator Award for his contributions to quality of care research.
On March 28, the U.S. Food and Drug Administration approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sameer Bellapravalu, MD 3000 Staunton Ave Se, Unit # 11, Charleston, WV 25304-1145 Ph: (304) 388-5435 | Dr Sameer Bellapravalu, MD 1 Hospital Drive Room 313, Psychiatry Dept Dc067.00, Columbia, MO 65212-0001 Ph: (573) 884-6136 |
News Archive
"The Global Fund to Fight AIDS, Tuberculosis and Malaria signed a grant agreement worth $102 million with the Churches Health Association of Zambia [CHAZ] Wednesday," Devex's "Development Newswire" reports.
Tolerx, Inc., today announced the publication in Diabetologia, the journal of the European Association for the Study of Diabetes, of the four-year follow-up clinical data from new onset type 1 diabetes (T1DM) patients (age 12-39) who received a single short course of therapy with otelixizumab (ChAglyCD3).
Adam Rose, MD, MSc, an assistant professor of medicine at Boston University School of Medicine, has accepted the Society of General Internal Medicine's New England Region 2011 Clinician Investigator Award for his contributions to quality of care research.
On March 28, the U.S. Food and Drug Administration approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS).
› Verified 2 days ago
Dr. Anasseril E Daniel, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 33 E Broadway Ste 115, Columbia, MO 65203 Phone: 573-443-6930 Fax: 573-875-4272 | |
Dr. Joseph J. Parks, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: Family Health Center Of Boone County, 1001 West Worley, Columbia, MO 35203 Phone: 573-214-2314 Fax: 573-814-2784 | |
Dr. Robert Edward Frazier, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 367 Crown Pt, Columbia, MO 65203 Phone: 573-442-4346 Fax: 573-443-2027 | |
Myles Brandon Goble, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 525 N. Keene Street, Suite 301, Columbia, MO 65201 Phone: 573-882-2260 Fax: 573-884-4249 | |
Ashutosh Pandey, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1020 Hitt St, Columbia, MO 65212 Phone: 573-882-1515 | |
Jeffrey Thiele, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 800 Hospital Dr, Columbia, MO 65201 Phone: 573-814-6000 | |
Lisa A Lacey, D.O. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 800 Hospital Dr, Columbia, MO 65201 Phone: 573-814-6480 |